FY26 results reported
As filed · Financial Results
EarningsMajormateriality 77 out of 100
What happened
FactFinancial Results. Phiroze Jeejeebhoy Towers,. Approved the standalone and consolidated un-audited Financial Results along.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
RevisedEarlierFY25
Our revenue reached ₹783 crore, marking a 10% increase over the previous year, supported by steady demand across our therapeutic portfolio.
NowFY25
Anti-inflammatory products, led by ibuprofen, grew 22% year-on-year to ₹148 crore.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved -81.10%.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Aim to add 8-10 products in the next 12-18 months in existing and new therapeutic areas (management committed by H1 FY27)
- Looking ahead, we are building a robust pipeline of high-potential molecules. (management committed by H1 FY27)
Evidence
- SMS Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
- Earlier statement · FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%